Marizyme, Inc. (OTCPK: MRZM)
Health Care · Biotechnology · US
$—
— today · — 1Y
Marizyme, Inc. (OTCPK: MRZM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $132.00 and employs 13 people.
trading between 0.00 and 0.12.
Tweenvest scores Marizyme, Inc. across four factors: quality 15/100, value 45/100. Its strongest factor is value.
MRZM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $132.00
- Revenue (TTM)
- $183.42K
- P/E
- —
- EPS
- -0.13
- Dividend yield
- —
- Beta (5Y)
- 0.86
- 52-week high
- $0.12
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 131.79M
- Employees
- 13
- Next earnings
- —
About Marizyme, Inc.
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
- ISIN
- US5703721028
- Founded
- 2007
- Listed since
- Nov 10, 2010
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.